Skip to main content

Table 1 Baseline characteristics in study patients with and without events

From: Association of circulating PCSK9 concentration with cardiovascular metabolic markers and outcomes in stable coronary artery disease patients with or without diabetes: a prospective, observational cohort study

 

Total (n = 1225)

Non-events (n = 1122)

Events (n = 103)

p value

Clinical characteristics

 Age (years)

57.8 ± 10.1

57.7 ± 10.0

58.5 ± 10.8

0.419

 Male sex

833 (68.0)

765 (68.3)

68 (66.0)

0.653

 BMI (kg/m2)

25.9 ± 3.3

25.9 ± 3.2

26.0 ± 4.1

0.704

 Hypertension

854 (69.7)

781 (69.6)

73 (70.9)

0.789

 Family history of CAD

289 (23.6)

275 (24.5)

14 (13.6)

0.013

 Diabetes mellites

377 (30.8)

327 (29.1)

50 (48.5)

 < 0.001

 Current smoker

481 (39.3)

440 (39.2)

41 (39.8)

0.907

 Drinking

284 (23.2)

261 (23.3)

23 (22.3)

0.830

Laboratory parameters

 FPG (mmol/L)

5.9 ± 1.9

5.9 ± 1.8

6.3 ± 3.1

0.042

 HbA1C (%)

6.2 ± 1.1

6.2 ± 1.1

6.4 ± 1.1

0.036

 ALT (U/L)

20(15,29)

20 (15,29)

20 (14,31)

0.905

 Creatinine (μmol/L)

77.7 ± 17.5

77.6 ± 16.9

79.1 ± 23.0

0.408

 TC (mmol/L)

4.82 ± 0.96

4.80 ± 0.95

5.02 ± 0.95

0.028

 TG (mmol/L)

1.61 (1.16,2.32)

1.6 (1.15,2.31)

1.72 (1.31,2.43)

0.215

 HDL-C (mmol/L)

1.09 ± 0.32

1.09 ± 0.32

1.15 ± 0.38

0.060

 LDL-C (mmol/L)

3.15 ± 0.85

3.13 ± 0.85

3.35 ± 0.85

0.013

 PCSK9 (ng/mL)

234.52 (194.79,276.13)

232.99 (193.72,274.16)

264.26 (219.45,309.86)

 < 0.001

 Fibrinogen (μg/mL)

3.1 ± 0.8

3.1 ± 0.7

3.3 ± 1.1

0.006

 NT-proBNP (pg/mL)

51.9 (31.0,109.3)

50.9 (30.1,111.0)

58.1 (38.1,96.7)

0.172

Diseased vessels

 One vessel

438 (35.8)

411 (36.6)

27 (26.2)

 

 Two vessels

365 (29.8)

340 (30.3)

25 (24.3)

 

 Three vessels

422 (34.4)

371 (33.1)

51 (49.5)

 

 LVEF (%)

64.7 ± 6.7

64.7 ± 6.7

64.8 ± 6.6

0.882

 Gensini score

27 (11,44)

26 (10,42)

35.08 (18,60)

0.003

Medications

 Aspirin

464 (37.9)

431 (38.4)

33 (32.0)

0.202

 Clopidogrel

130 (10.6)

123 (11.0)

7 (6.8)

0.189

 ACEI/ARB

252 (20.6)

235 (20.9)

17 (16.5)

0.286

 β-blockers

238 (19.4)

226 (20.1)

12 (11.7)

0.037

  1. PCSK9 proprotein convertase subtilisin/kexin type 9, BMI body mass index, CAD coronary artery disease, FPG fasting plasma glucose, HbA1C hemoglobin A1C, ALT alanine aminotransferase, TC total cholesterol, TG triglyceride, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, NT-proBNP N-Terminal pro-brain natriuretic peptide, LVEF left ventricular ejection fraction, ACEI angiotensin converting enzyme inhibitors, ARB angiotensin receptor blockers, p < 0.05 suggests significant difference